Logo.png
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
August 19, 2021 09:27 ET | Vyant Bio, Inc.
CDKL5 Deficiency Disorder (“CDD”) is a severe neurodevelopmental epileptic encephalopathy disorder with no effective treatments or cureCollaboration creates opportunities to identify, validate, and...
trypf.png
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
July 28, 2021 08:30 ET | Tryp Therapeutics Inc.
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"),...
LOGO.jpg
Vivos Inc Extends it Intellectual Property Protection
December 01, 2020 09:30 ET | Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
Reports and Data.jpeg-01
Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026 | Reports and Data
March 23, 2020 15:00 ET | Reports and Data
New York, March 23, 2020 (GLOBE NEWSWIRE) -- The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a CAGR of...
Logo.jpg
Celsion Corporation Announces Issuance of New Patent for ThermoDox®
April 17, 2019 08:00 ET | Celsion CORP
 Represents a Significant Advance for Celsion’s Life Cycle Management Program for ThermoDox®           Establishing Bioequivalence Will Extend Market Exclusivity to 2033 LAWRENCEVILLE, N.J,...
Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
March 26, 2019 03:00 ET | NANOBIOTIX
Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United StatesPre-IND feedback from US Food and Drug Administration (FDA) provides clarity to...
Nanobiotix annonce son plan d’enregistrement clinique dans les cancers de la Tête et du Cou avec NBTXR3 aux Etats-Unis à la suite du retour de la FDA
March 26, 2019 03:00 ET | NANOBIOTIX
Préparation d’une étude clinique évènementielle, randomisée et évaluant la survie globale (SG) aux États-UnisLe retour (pre-IND) de la Food and Drug Administration (FDA) permet de clarifier l’approche...
provectus_logo.jpg
PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS
April 24, 2018 07:00 ET | Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...
provectus_logo.jpg
SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY
April 19, 2018 06:00 ET | Provectus Biopharmaceuticals Inc.
FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...